Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

 

FORM 25

 

 

NOTIFICATION OF REMOVAL FROM LISTING

AND/OR REGISTRATION UNDER SECTION 12(b)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-38485

 

 

Amneal Pharmaceuticals, Inc., New York Stock Exchange

(Exact name of Issuer as specified in its charter, and name of Exchange

where security is listed and/or registered)

 

 

400 Crossing Blvd

Bridgewater, NJ, 08807

[phone]

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

Class A Common Stock, par value $0.01 per share

(Description of class of securities)

 

 

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

 

☐	17 CFR 240.12d2-2(a)(1)

 

☐	17 CFR 240.12d2-2(a)(2)

 

☐	17 CFR 240.12d2-2(a)(3)

 

☐	17 CFR 240.12d2-2(a)(4)

 

☐	Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.(1)

 

☒	Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Amneal Pharmaceuticals, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

 

December 26, 2023						/s/ Anastasios Konidaris				Executive Vice President and Chief Financial Officer
Date						Name: Anastasios Konidaris				Title

 

(1)	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions

 

 

 

---